“Deucravacitinib in Plaque Psoriasis: 3-year Safety and Efficacy Results from the Phase 3 POETYK PSO-1 and PSO-2 Trials”, J of Skin, vol. 8, no. 2, p. s366, Mar. 2024, doi: 10.25251/skin.8.supp.366.